title: [18F-FDG PET/CT contributes to diagnostics and therapy monitoring of radiation-induced angiosarcoma].
abstract: Angiosarcomas are rare, aggressive malignant mesenchymal tumours with a poor prognosis. Radiation therapy is an independent risk factor for the development of secondary angiosarcoma. The onset of angiosarcoma may resemble benign lesions, leading to delayed diagnosis. It has been suggested that 18F-fluorodeoxyglucose (FDG) PET/CT scan may be useful in the early diagnosis in differentiating angiosarcoma from benign lesions and in therapy monitoring. We report the utility of 18F-FDG PET/CT scan in the diagnosis and follow-up of radiation-induced angiosarcoma in a patient previously treated for uterine cancer.
authors.affiliation: francesca.cucchi@regionh.dk.
authors.forename: Francesca
authors.initials: F
authors.lastname: Cucchi
authors.forename: Jens
authors.initials: J
authors.lastname: Bülow
authors.forename: Lene
authors.initials: L
authors.lastname: Simonsen
authors.forename: Lotte
authors.initials: L
authors.lastname: Nedergaard
authors.forename: Christian
authors.initials: C
authors.lastname: Haarmark
authors.forename: Ali
authors.initials: A
authors.lastname: Asmar
mesh_terms: D000008:Abdominal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006394:Hemangiosarcoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009381:Neoplasms, Radiation-Induced / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18